Digital rectal examination, serum prostatic specific antigen or transrectal ultrasonography: The best tool to guide the treatment of men with benign prostatic hyperplasia

Current Opinion in Urology

Volumn 19, Issue 1, 2009, Pages 44-48

  Kijvikai, Kittinut ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Benign prostatic hyperplasia; Digital rectal examination; Prostate volume; Serum prostatic specific antigen; Transrectal or transabdominal prostate ultrasound

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

CLINICAL EVALUATION; DIGITAL RECTAL EXAMINATION; DISEASE COURSE; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE HYPERTROPHY; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION;

DIGITAL RECTAL EXAMINATION; DISEASE PROGRESSION; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA;

EID: 58149260370     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32831743d0     Document Type: Review

References (24)

1. Fong YK, Milani S, Djavan B. Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. Curr Opin Urol 2005; 15:35-38.
2. Roehrborn CG, McConnell J, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163:13-20.
3. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158:481-487.
4. Marberger MJ, Andersen JT, Nickel JC, et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol 2000; 38:563-568.
5. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338:557-563.
6. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170 (2 Pt 1):530-547.
7. Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004; 46:547-554.
8. Carvalhal GF, Smith DS, Mager DE, et al. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml. or less. J Urol 1999; 161:835-839.
9. Bosch JL, Bohnen AM, Groeneveld FP. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study. Eur Urol 2004; 46:753-759.
10. Carter HB, Landis P, Wright EJ, et al. Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life? J Urol 2005; 173:2040-2043.
11. Bohnen AM, Groeneveld FP, Bosch JL. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol 2007; 51:1645-1652. A large longitudinal community-based study demonstrates the strong association between serum PSA and prostate volume.
12. Wright EJ, Fang J, Metter EJ, et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol 2002; 167:2484-2487.
13. Mochtar CA, Kiemeney LA, van Riemsdijk MM, et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 2003; 44:695-700.
14. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387-2398.
15. Chung BH, Hong SJ, Cho JS, Seong DH. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study. BJU Int 2006; 97:742-746.
16. Laniado ME, Ockrim JL, Marronaro A, et al. Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU Int 2004; 94:1283-1286.
17. Mochtar CA, Kiemeney LA, Laguna MP, et al. PSA velocity in conservatively managed BPH: can it predict the need for BPH-related invasive therapy? Prostate 2006; 66:1407-1412.
18. Nickel JC. Benign prostatic hyperplasia: does prostate size matter? Rev Urol 2003; 5 (Suppl 4):S12-S17.
19. Kanao K, Kikuchi E, Nakashima J, et al. Three-dimensional ultrasonography in evaluation of benign prostatic hyperplasia. Int J Urol 2004; 11:1087-1091.
20. Chia SJ, Heng CT, Chan SP, Foo KT. Correlation of intravesical prostatic protrusion with bladder outlet obstruction. BJU Int 2003; 91:371-374.
21. Lim KB, Ho H, Foo KT, et al. Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of bladder outlet obstruction. Int J Urol 2006; 13:1509-1513.
22. Mariappan P, Brown DJ, McNeill AS. Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study. J Urol 2007; 178:573-577. This cohort study demonstrates the impact of IPP to predict the outcome of a TWOC.
23. Marks LS, Roehrborn CG, Andriole GL. Prevention of benign prostatic hyperplasia disease. J Urol 2006; 176 (4 Pt 1):1299-1306.
24. Ruszat R, Wyler SF, Seftz M, et al. Comparison of potassium-titanylphosphate laser vaporization of the prostate and transurethral resection of the prostate: update of a prospective nonrandomized two-centre study. BJU Int 2008. [Epub ahead of print].